Remi Laberge
Company: Arda Therapeutics
Job title: Co-Founder & Chief Technology Officer
Seminars:
11:45 am Reducing & Reversing Liver Fibrosis Using Targeted Elimination of Pathogenic Stellate Cells 11:45 am
Identifying pathogenic stellate cells using advanced markers for targeting the primary drivers of liver fibrosis Developing antibody drug conjugate for the selective delivery of payloads directly to pathogenic stellate cells to minimize off-target effects Establishing the in vivo pharmacokinetic and pharmacodynamic relationship for optimizing dosing, predicting efficacy, and ensuring safety in reducing liver fibrosisRead more
day: Conf day 2